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ABSTRACT
Introduction: Since chronic obstructive pul-
monary disease (COPD) is a heterogeneous
condition, a composite endpoint of clinically
important deterioration (CID) may provide a
more holistic assessment of treatment efficacy.
We compared long-acting muscarinic
antagonist/long-acting b2-agonist combination
therapy with tiotropium/olodaterol versus tio-
tropium alone using a composite endpoint for
CID. CID was evaluated overall and in patients
with low exacerbation history (at most one
moderate exacerbation in the past year [not
leading to hospitalisation]), Global Initiative for
Chronic Obstructive Lung Disease (GOLD) 2
patients and maintenance-naı̈ve patients with
COPD. We assessed whether early treatment
optimisation is more effective with tiotropium/
olodaterol versus tiotropium in delaying and
reducing the risk of CID.
Electronic supplementary material The online
version of this article (https://doi.org/10.1007/s12325-
020-01528-2) contains supplementary material, which is
available to authorized users.
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Methods: Data were analysed from 2055
patients treated with either tiotropium/olo-
daterol 5/5 lg or tiotropium 5 lg (delivered via
Respimat) in two replicate, 52-week, parallel-
group, double-blind studies (TONADO 1/2).
CID was defined as a decline of at least 0.1 L
from baseline in trough forced expiratory vol-
ume in 1 s, increase from baseline of at least
4 units in St. George’s Respiratory Question-
naire score, or moderate/severe exacerbation.
Time to first occurrence of one of these events
was recorded as time to first CID.
Results: Overall, treatment with tiotropium/
olodaterol significantly increased the time to,
and reduced the risk of, CID versus tiotropium
(median time to CID 226 versus 169 days; haz-
ard ratio [HR] 0.76 [95% confidence interval
0.68, 0.85]; P\0.0001). Significant reductions
were also observed in patients with low exacer-
bation history (241 versus 170; HR 0.73 [0.64,
0.83]; P\0.0001), GOLD 2 patients (241 versus
169; 0.72 [0.61, 0.84]; P\0.0001) and mainte-
nance-naı̈ve patients (233 versus 171; 0.75
[0.62, 0.91]; P = 0.0030).
Conclusion: In patients with COPD, including
patients with low exacerbation history, GOLD 2
patients and maintenance-naı̈ve patients, tio-
tropium/olodaterol reduced the risk of CID
versus tiotropium. These results demonstrate
the advantages of treatment optimisation with
tiotropium/olodaterol over tiotropium
monotherapy.
Trial Registration: ClinicalTrials.gov identifier:
TONADO 1 and 2 (NCT01431274 and
NCT01431287, registered 8 September 2011).
Graphic Abstract:
PLAIN LANGUAGE SUMMARY
COPD is a complicated disease that deteriorates
over time. Worsening of COPD is associated
with the lungs working less effectively, a fall in
quality of life and a rise in sudden flare-ups of
the disease. In this study, we looked at lung
function, quality of life and flare-ups together
using a measure called ‘‘clinically important
deterioration’’ (CID). We looked at 2055 people
with COPD to compare the effects of taking two
bronchodilators (tiotropium and olodaterol)
against taking one bronchodilator (tiotropium
alone). Bronchodilators are a type of inhaled
medication that relax the muscles in the lungs
and widen airways, making it easier to breathe.
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They have also been shown to reduce sudden
flare-ups of COPD. Across a wide range of peo-
ple with COPD, we found that treatment with
tiotropium/olodaterol reduced the risk of a CID
compared with tiotropium alone. This includes
in those patients at an early stage of disease,
who may benefit from finding the best treat-
ment option for them as early as possible.
Keywords: Chronic obstructive pulmonary
disease; Exacerbations; Health status; Lung
function; Olodaterol; Tiotropium
Key Summary Points
Why carry out this study?
Since chronic obstructive pulmonary
disease (COPD) is a heterogenous disease,
using a composite endpoint that
incorporates lung function, exacerbations
and quality of life may provide a more
holistic view of the potential benefits of a
given therapy and increase our ability to
detect differences between therapies.
Further studies are needed to ascertain
whether more patients with COPD,
including those with mild-to-moderate or
few symptoms, could benefit from earlier
treatment with long-acting muscarinic
antagonist/long-acting b2-agonist
combination therapy.
In this post hoc analysis of data from the
TONADO studies, we used a composite
endpoint for clinically important
deterioration (CID) that included
assessments of lung function, health
status and exacerbations to compare the
effects of treatment with tiotropium/
olodaterol versus tiotropium in patients
with COPD.
What was learned from the study?
Overall, in 2055 patients with moderate-
to-very severe COPD from the TONADO
trials, tiotropium/olodaterol significantly
reduced the risk of a CID compared with
tiotropium alone.
Results were similar for patients
considered to be at an earlier stage of
COPD (patients with low exacerbation
history [at most one moderate
exacerbation], Global Initiative for
Chronic Obstructive Lung Disease 2
patients and maintenance-naı̈ve patients),
suggesting that early treatment with
tiotropium/olodaterol may be more
effective in reducing the risk of a CID
versus tiotropium.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, graphical abstract and
plain language summary to facilitate under-
standing of the article. To view digital features for
this article go to https://doi.org/10.6084/m9.
figshare.13061345.
INTRODUCTION
Whether more patients with chronic obstructive
pulmonary disease (COPD), including those with
mild-to-moderate disease or fewer symptoms,
could benefit from earlier treatment with long-
actingmuscarinicantagonist (LAMA)/long-acting
b2-agonist (LABA) combination therapy is a mat-
ter of debate [1, 2]. The Global Initiative for
Chronic Obstructive Lung Disease (GOLD) 2020
report recommends LAMAor LABAmonotherapy
as initial pharmacological therapy for most
patients [3]. Dual LAMA/LABA therapy is recom-
mended for patients with COPD who remain
symptomatic despite treatment with a single
long-acting bronchodilator, or as initial therapy
for patients who are highly symptomatic (COPD
Assessment TestTM [CAT][20) and classified as
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being in GOLD group D (at least two moderate
exacerbations or at least one leading to hospitali-
sation,modifiedBritishMedicalResearchCouncil
questionnaire [mMRC] grade C 2 and CAT C 10)
or for patients in GOLD group B (at most one
moderate exacerbation, mMRC grade C 2 and
CAT C 10) with severe breathlessness [3]. The
report does, however, acknowledge the lack of
high-quality evidence to support initial pharma-
cological treatment strategies in patients with
newly diagnosed COPD [3]. In contrast, the
American Thoracic Society 2020 clinical practice
guidelines recommend LAMA/LABA combina-
tion therapy over LABA or LAMA monotherapy
for patientswithCOPDwith dyspnoea or exercise
intolerance [4]. Additionally, the National Insti-
tute for Health and Care Excellence recommends
dual LAMA/LABA therapy for patients with no
indication of asthmatic features or corticosteroid
responsiveness who remain breathless or have
exacerbations despite optimised non-pharmaco-
logical management and use of short-acting
bronchodilators [5].
The benefits of LAMA/LABA combination
therapy versus LAMA or LABA monotherapies
have consistently been demonstrated in
patients with COPD, including improvements
in lung function, health status and symptoms
[3, 6–9]. This was exemplified by Oba et al. [9] in
a recent network analysis of more than 100,000
patients with moderate-to-very severe COPD
from 99 studies. The results showed that LAMA/
LABA reduced COPD exacerbations compared
with either LAMA or LABA monotherapy or a
LABA/inhaled corticosteroid (ICS) combination;
this finding was true for both patients with high
or low exacerbation risk [9]. Greater improve-
ments in symptom and quality-of-life scores,
and similar safety outcomes, were also observed
with combination therapy versus monotherapy
[9]. In addition, post hoc analysis of data from
the TONADO and OTEMTO trials showed sig-
nificant improvements in lung function, health
status and breathlessness with tiotropium/olo-
daterol versus tiotropium both in patients who
were naı̈ve to LAMA, LABA and ICS therapy at
study entry [10] and in patients receiving only
LAMA monotherapy at study entry [11].
Notably, the majority of studies comparing
LAMA/LABA combination therapy with
monotherapy have assessed lung function as a
means of evaluating the effectiveness of treat-
ment regimens [12]. In addition, reporting of
exacerbation rates and time to first exacerbation
are often regulatory requirements for drug regis-
tration, leading to their prominence over other
endpoints [13]. However, the GOLD 2020 report
advises that symptomsaswell as exacerbations are
taken into account when considering combina-
tion therapyasa treatmentoption [3],whilemany
clinicians prioritise improvements in both symp-
toms and quality of life. Given the heterogeneous
nature of COPD, using a composite endpoint that
incorporates lung function, exacerbations and
quality of life has the potential to provide a more
holistic view of the potential benefits of a given
therapy and increase the ability to detect differ-
ences between interventions.
Care must be taken in selecting the right
composite endpoint components, which must
be clinically meaningful and help to guide
medical decision-making [14]. Clinically rele-
vant thresholds for change have been established
for several parameters that may be included in a
composite endpoint, including forced expiratory
volume in 1 s (FEV1) [15] and the St. George’s
Respiratory Questionnaire (SGRQ) score [16].
These thresholds, termed the minimal clinically
important difference (MCID), represent the
smallest difference in score that patients perceive
as beneficial and that would mandate a change
in the patient’s management [17].
In COPD, a number of recent studies have
explored the use of composite endpoints
[18–24], several of which include components
with MCIDs [18–20]. Clinically important dete-
rioration (CID) is one such composite measure
that has been used to assess COPD worsening.
Since preventing disease progression is a major
goal of COPD [3], CID provides a valuable mea-
sure. Post hoc analysis of clinical trials has
demonstrated that LAMA/LABA reduces the risk
of CID (encompassing lung function, health
status and the occurrence of moderate-to-severe
exacerbations) compared with LAMA or LABA
monotherapy, LABA/ICS or placebo [18, 19].
The aim of this post hoc analysis was to use a
composite endpoint to assess whether tio-
tropium/olodaterol is more effective than tio-
tropium alone in delaying CID in patients from
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the TONADO 1 and 2 trials, specifically in
patients at an earlier stage of disease or with a
lower disease burden. Patients were assessed
overall and in the following subgroups: patients
with low exacerbation history (at most one
moderate exacerbation and no exacerbations
leading to hospitalisation in the past year);
patients with GOLD 2 COPD (moderate COPD);
and patients who were naı̈ve to COPD mainte-
nance therapy (maintenance-naı̈ve). In addi-
tion, this study will help to evaluate the utility
of CID as a metric for monitoring COPD wors-
ening in patients receiving different treatments.
METHODS
The TONADO trials have been described in
detail previously [25] and are briefly sum-
marised below. TONADO 1 (NCT01431274)/
TONADO 2 (NCT01431287) were two repli-
cate, 52-week, parallel-group, double-blind
studies. In total, 5162 patients were treated with
either tiotropium/olodaterol 2.5/5 lg or 5/5 lg,
tiotropium 2.5 lg or 5 lg, or olodaterol 5 lg
(delivered once daily via Respimat). Patients
were aged at least 40 years, with a smoking
history of more than 10 pack-years and moder-
ate-to-very severe COPD (GOLD 2–4). For fur-
ther details, see the Supplementary Methods.
The primary endpoints assessed were FEV1 area
under the curve from 0 to 3 h response, trough
FEV1 response and SGRQ total score at 24 weeks
[25].
The TONADO studies were performed in
accordance with the Declaration of Helsinki,
International Conference on Harmonisation
Harmonised Tripartite Guideline for Good
Clinical Practice and local regulations. The
protocols were approved by the authorities and
the ethics committees of the respective institu-
tions, and signed informed consent was
obtained from all patients.
Definition and Assessment of CID
In this post hoc analysis, we used a composite
endpoint to evaluate the time to first CID. The
composite endpoint was defined as a decline
from baseline in trough FEV1 of at least 0.1 L,
increase from baseline of at least 4 units in
SGRQ score, or moderate or severe exacerba-
tion, as previously defined by Singh et al. [19].
The time to first occurrence of one of these
events was recorded as the time to first CID.
Assessment of trough FEV1 was performed on
day 1 and at weeks 2, 6, 12, 18, 24, 32, 40 and
52. Assessment of SGRQ was completed on
day 1 and after 12, 24 and 52 weeks [25]. Data
are presented for comparisons of tiotropium/
olodaterol 5/5 lg and tiotropium 5 lg.
Statistical Analysis
Time to first CID (composite endpoint) and
time to first clinically significant event (indi-
vidual components of the composite endpoint)
were measured in days. The 25th percentiles for
the individual components, and the medians
for the composite endpoint (overall and for
each patient subgroup), are reported for each
treatment arm wherever estimable.
Hazard ratios (HRs) for treatment compar-
isons were obtained by fitting a Cox propor-
tional hazard regression model, with study, ICS
use at baseline, region, GOLD stage and smok-
ing status as fixed categorical effects, and with
baseline SGRQ score and the number of exac-
erbations in the previous year as fixed contin-
uous covariates.
Kaplan–Meier estimates of the probability of
CID based on the composite endpoint and for
the individual components of the composite
endpoint were generated for the total study
population.
RESULTS
Baseline Characteristics in the TONADO
Studies
This post hoc analysis evaluated data from 2055
patients treated with either tiotropium/olo-
daterol 5/5 lg or tiotropium 5 lg in the
TONADO 1 and 2 trials. Baseline demograph-
ics were similar between the two treatment arms
(Supplementary Table 1) and have been descri-
bed previously [25]. The majority of patients
were male (tiotropium/olodaterol, 71.2%;
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tiotropium, 73.1%), with a mean age approx.
64 years (mean ± standard deviation
63.8 ± 8.3; 63.9 ± 8.6) and over one-third were
current smokers (38.9%; 35.8%). The majority
of patients were classified as GOLD stage 2
(tiotropium/olodaterol, 48.8%; tiotropium,
50.0%) or stage 3 (tiotropium/olodaterol,
39.7%; tiotropium, 37.5%); the remaining
patients were classified as GOLD stage 4 (tio-
tropium/olodaterol, 11.6%; tiotropium, 12.4%).
At baseline, pre- and post-bronchodilator
screening for FEV1 were similar in the tio-
tropium/olodaterol (1.180 ± 0.493 L and
1.344 ± 0.505 L, respectively) and tiotropium
(1.200 ± 0.504 L and 1.370 ± 0.521 L) groups.
CID Composite Endpoint
When the CID composite endpoint was used,
median time to event was delayed and the risk
of CID was significantly reduced in patients
treated with tiotropium/olodaterol compared
with tiotropium in the total patient population
(time to event 226 versus 169 days; HR 0.76
[95% CI 0.68, 0.85]; P\0.0001) (Fig. 1).
Kaplan–Meier estimates also show a reduced risk
of CID and a longer time to event for patients
treated with tiotropium/olodaterol versus tio-
tropium, and clear separation between the two
treatment arms (Fig. 2).
A similar and significant delay in median
time to CID and reduction in risk of CID with
tiotropium/olodaterol versus tiotropium alone
was also observed in the three subpopulations
assessed: patients with low exacerbation history
(241 versus 170; HR 0.73 [95% CI 0.64, 0.83];
P\ 0.0001), GOLD 2 patients (241 versus 169;
HR 0.72 [95% CI 0.61, 0.84]; P\ 0.0001) and
maintenance-naı̈ve patients (233 versus 171; HR
0.75 [95% CI 0.62, 0.91]; P = 0.0030) (Fig. 1).
Individual Components of the Composite
Endpoint
Overall Patient Population
Overall, there was a significant reduction in the
risk of trough FEV1 decline from baseline of at
least 0.1 L (HR 0.69 [95% CI 0.59, 0.80];
P\ 0.0001) and in the risk of SGRQ score
increase from baseline of at least 4 units (HR 0.80
[95%CI0.68, 0.93];P = 0.0046)with tiotropium/
olodaterol versus tiotropium (Table 1). Therewas
also a reduction in the risk of moderate or severe
exacerbations (HR 0.86 [95% CI 0.73, 1.02];
Fig. 1 Treatment comparison and time to event for
tiotropium (5 lg) versus tiotropium/olodaterol (5/5 lg)
using the CID composite endpoint score. aLow exacerba-
tion history was defined as at most one moderate
exacerbation in the past year (not leading to
hospitalisation). CI confidence interval, CID clinically
important deterioration, GOLD Global Initiative for
Chronic Obstructive Lung Disease, T/O tiotropium/
olodaterol, Tio tiotropium
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P = 0.0749) with tiotropium/olodaterol versus
tiotropium.
In patients treated with tiotropium/olo-
daterol versus tiotropium, 29.8% versus 37.6%
experienced a trough FEV1 decline from
Fig. 2 Time to first CID in patients treated with tiotropium (5 lg) versus tiotropium/olodaterol (5/5 lg) in the overall
patient population. CID clinically important deterioration, T/O tiotropium/olodaterol, Tio tiotropium
Table 1 Individual components of the composite endpoint: event rates and time to first event (25th percentile) in the total
patient population















































CI confidence interval, FEV1 forced expiratory volume in 1 s, HR hazard ratio, SGRQ St. George’s Respiratory
Questionnaire
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baseline of at least 0.1 L, 29.6% versus 35.5% an
SGRQ score increase from baseline of at least
4 units, and 27.8% versus 28.9% experienced
moderate or severe exacerbations (Table 1).
Patients with Low Exacerbation History
For patients with low exacerbation history,
there was a significant reduction in the risk of
trough FEV1 decline (HR 0.68 [95% CI 0.57,
0.81]; P\0.0001) and in the risk of SGRQ score
increase from baseline (HR 0.74 [95% CI 0.62,
0.89]; P = 0.0011) with tiotropium/olodaterol
compared with tiotropium (Table 2). The risk
was also reduced for moderate or severe exac-
erbations, but the reduction was not statistically
significant between treatment groups (Table 2).
In patients with low exacerbation history
who received treatment with tiotropium/olo-
daterol versus tiotropium, 29.8% versus 38.3%
of patients experienced a trough FEV1 decline
from baseline of at least 0.1 L, 29.1% versus
36.9% experienced an SGRQ score increase from
baseline of at least 4 units, and 24.3% versus
25.5% experienced moderate or severe exacer-
bations (Table 2).
GOLD 2 Patients
For GOLD 2 patients, there was a significant
reduction in the risk of trough FEV1 decline
with tiotropium/olodaterol versus tiotropium
(HR 0.67 [95% CI 0.55, 0.82]; P\ 0.0001). There
was a reduction of 14% in the risk of SGRQ score
increase from baseline and 21% in the risk of
moderate or severe exacerbations for patients
treated with tiotropium/olodaterol versus tio-
tropium, although neither of these reductions
were statistically significant (Table 3).
In GOLD 2 patients treated with tiotropium/
olodaterol versus tiotropium, 34.1% versus
44.4% of patients experienced a trough FEV1
decline from baseline of at least 0.1 L, 30.1%
versus 34.3% experienced an SGRQ score
increase from baseline of at least 4 units, and
20.6% versus 24.8% experienced moderate or
severe exacerbations (Table 3).
Maintenance-Naı̈ve Patients
In maintenance-naı̈ve patients, there was a sig-
nificant reduction in the risk of trough FEV1
decline with tiotropium/olodaterol compared
with tiotropium (HR 0.56 [95% CI 0.44, 0.72];
Table 2 Individual components of the composite endpoint: event rates and time to first event (25th percentile) in patients
with low exacerbation history (B 1 moderate exacerbation in the past year)
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Table 3 Individual components of the composite endpoint: event rates and time to first event (25th percentile) in
GOLD 2 patients
Endpoint Tiotropium 5 lg Tiotropium/olodaterol
5/5 lg























Trough FEV1 decline from








SGRQ score increase from

















CI confidence interval, FEV1 forced expiratory volume in 1 s, HR hazard ratio, SGRQ St. George’s Respiratory
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Table 4 Individual components of the composite endpoint: event rates and time to first event (25th percentile) in
maintenance-naı̈ve patients
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P\ 0.0001). No other components of the com-
posite endpoint were statistically significant for
comparison of tiotropium/olodaterol versus
tiotropium (Table 4). Although the treatment
comparison was not statistically significant for
SGRQ score, a 16% reduction in the risk of
SGRQ score increase from baseline was observed
with tiotropium/olodaterol versus tiotropium
(Table 4).
In maintenance-naı̈ve patients treated with
tiotropium/olodaterol versus tiotropium, 29.4%
versus 44.5% of patients experienced a trough
FEV1 decline from baseline of at least 0.1 L,
27.1% versus 31.7% experienced an SGRQ score
increase from baseline of at least 4 units, and
19.4% versus 19.4% experienced moderate or
severe exacerbations (Table 4).
Safety
Safety data from the TONADO trials have been
published previously [25]. In brief, the propor-
tion of patients with adverse events was similar
in those treated with tiotropium/olodaterol
versus tiotropium (74.0% versus 73.3%), as was
the proportion of patients discontinuing treat-
ment due to an adverse event (7.4% versus
9.0%). The most frequently reported adverse
events were respiratory, thoracic and mediasti-
nal disorders (39.4% for tiotropium/olodaterol
versus 42.7% for tiotropium), COPD (32.3%
versus 32.9%), and infections and infestations
(36.3% versus 33.7%). The incidence of pneu-
monia was similar in those treated with tio-
tropium/olodaterol versus tiotropium (3.3%
versus 2.5%).
DISCUSSION
Findings from the TONADO 1 and 2 studies
have previously shown that the once-daily
LAMA/LABA combination of tiotropium and
olodaterol improves lung function, breathless-
ness and quality of life in patients with mod-
erate-to-very severe COPD compared with
tiotropium alone [25–27]. This post hoc analysis
of data from the two TONADO COPD trials
further demonstrated that tiotropium/
olodaterol significantly reduces the risk of a CID
versus tiotropium alone.
The definition of CID assessed here has been
described previously, and our findings are in
line with recent studies by Singh et al. [19],
Anzueto et al. [18] and Rabe et al. [20], all of
whom used the same CID composite endpoint.
Singh et al. [19] demonstrated that the risk of a
first CID was reduced with LAMA/LABA (ume-
clidinium/vilanterol) versus monotherapy with
either tiotropium, umeclidinium or vilanterol,
or versus placebo in symptomatic patients with
COPD. Similarly, Anzueto et al. showed that
LAMA/LABA (indacaterol/glycopyrronium) had
significant treatment benefits over tiotropium
monotherapy in patients with moderate-to-
severe COPD, as well as versus LABA/ICS [18].
Our findings for the risk of reaching a CID
were remarkably similar in the overall patient
population and among the three subpopula-
tions assessed. The subpopulation analysis
highlights the benefits of treatment with tio-
tropium/olodaterol versus tiotropium in
patients with either less severely impaired lung
function or a lower disease burden, i.e. GOLD 2
patients with moderate COPD, patients with
symptomatic COPD and a low risk of exacer-
bations, and maintenance-naı̈ve patients.
Maintenance-naı̈ve patients starting on tio-
tropium/olodaterol showed a 25% reduction in
the risk of a CID and a significant reduction
(44%) in the risk of lung function decline versus
those patients who initiated tiotropium. A
decrease in the risk of health status decline was
also observed with tiotropium/olodaterol versus
tiotropium in these patients; however, this did
not reach significance, likely because of the
smaller sample sizes in these subgroup analyses.
Overall, these observations suggest that starting
treatment with a LAMA/LABA combination
may be beneficial not only in improving COPD
outcomes but also in preventing disease wors-
ening. Current recommendations from GOLD
suggest that a LAMA/LABA combination should
only be used as initiation therapy in patients
with group D COPD who are highly symp-
tomatic or with group B COPD and severe
breathlessness [3]. However, our findings sug-
gest that patients with low exacerbation history
could benefit from earlier treatment with
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LAMA/LABA, and support the recent argument
put forward by Cazzola et al. [1] that LAMA/
LABA combination therapy could have benefits
as initial maintenance therapy. These findings
are supported by previous studies that have
consistently demonstrated LAMA/LABA combi-
nation therapy to be more effective than LAMA
or LABA monotherapy in improving lung
function and health status [1, 6, 8], and in
reducing the risk of exacerbations [1, 8, 9].
In addition to clinical evidence advocating
the benefits of dual bronchodilation [1], there is
a strong rationale for using LAMA/LABA as ini-
tial maintenance treatment. Pharmacologically,
the use of a LAMA/LABA combination exploits
both the adrenergic and cholinergic pathways
in the airway smooth muscle (ASM) to max-
imise bronchodilation. While LAMAs block the
effect of bronchoconstriction by blocking
acetylcholine binding to M3 muscarinic recep-
tors in ASM, activation of b2-adrenoreceptors by
LABAs induces ASM relaxation [1, 28]. In addi-
tion to controlling ASM constriction and
relaxation, muscarinic and adrenergic receptors
are located on inflammatory cells, and drugs
that target these receptors might also reduce
inflammation in COPD [1, 28]. Additionally,
LAMA/LABA is reported to have a good cardio-
vascular safety profile and does not increase
severe cardiovascular adverse events versus
monotherapy [1, 6, 29].
Analysis of the risk associated with the indi-
vidual components of the composite endpoint
clearly indicated that lung function was the
strongest driver of CID, both in the overall
patient population and in all three patient
subgroups. Given that this study evaluates dif-
ferent bronchodilator treatments, where the
most prominent effect is inevitably on lung
function, this finding is not surprising. Other
individual components also contributed to the
risk of CID observed, with the risk of health
status decline (as defined by the risk of SGRQ
score increase from baseline of at least 4 units),
showing a significant reduction with tio-
tropium/olodaterol versus tiotropium in the
total patient population and in patients with
low exacerbation history; this likely reflects the
benefits of improved lung function on overall
health, daily life and perceived well-being in
patients with COPD. In support of this, a recent
pooled analysis of 23 randomised controlled
COPD studies reported a correlation between
lung function and health status, with greater
improvements in trough FEV1 reported in
patients with better SGRQ scores [30]. Notably,
there was more variation observed between the
different patient subpopulations for moderate-
to-severe exacerbations.
Previous studies have demonstrated the
suitability of various composite endpoints to
predict long-term outcomes in patients with
COPD [21–24], including for CID [18–20].
Given that COPD is a progressive disease, the
use of CID as a composite endpoint provides a
valuable measure to monitor patients who do
not respond well to treatment but whose treat-
ments may prevent deterioration or disease
worsening—a major treatment goal for patients
with COPD [3]. The value of the composite
endpoint assessed here has previously been
demonstrated in a post hoc analysis of the
UPLIFT study, in which CID events at
6 months were shown to be a good predictor of
both future moderate or severe exacerbations
and severe exacerbations, as well as mortality
(albeit to a weaker extent) [20]. Using the same
definition of CID, data from two 3-year studies
(TORCH and ECLIPSE) reported similar find-
ings; patients who had an early CID (i.e. within
6–12 months of follow-up) consistently experi-
enced an increased long-term risk of lung
function and health status decline, exacerba-
tion and mortality [31].
General limitations associated with post hoc
analyses include the non-randomised nature of
the study and the lack of prespecified subgroups
[32]. Another limitation of this analysis was that
clinically significant events did not have to be
confirmed at a second clinic visit as an inclusion
criterion. This was a consequence of the length
of the TONADO studies (52 weeks) and the
number of assessments occurring during this
period (only three SGRQ assessments). A further
limitation is that the timings between clinically
significant events are not known, as only the
time to the first individual event was included
in the analysis. Instances where subsequent
clinically significant events occurred after the
first event were therefore not captured, nor was
Adv Ther
the order in which events occurred. In addition,
as described previously for similar CID analyses
[33], the most frequent events were those that
were recorded at distinct time points; since FEV1
and SGRQ were only assessed at the set study
visit dates, this limits the precision of the
Kaplan–Meier plots and HRs. Nonetheless, this
also reflects the manner in which assessments
would be conducted in clinical practice, where
physicians assess disease progression or treat-
ment failure at scheduled visits or based on
major events, such as exacerbations, which can
occur at any time.
CONCLUSION
In this post hoc analysis of data from the
TONADO studies, tiotropium/olodaterol
delayed the time to, and reduced the risk of,
CID compared with tiotropium alone in the
overall trial population, in patients with low
exacerbation history, patients with GOLD 2
COPD and in maintenance-naı̈ve patients.
Taken together with previous studies on tio-
tropium/olodaterol, LAMA/LABA combination
therapy versus monotherapy, these results sug-
gest that early treatment with tiotropium/olo-
daterol may be more effective than tiotropium
in reducing the risk of CID in these important
patient populations. In addition, the data
reported here support the use of CID endpoints
to monitor COPD disease progression, and
suggest that this could be a valuable metric to
assess in future randomised COPD trials.
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